Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telpegfilgrastim real-world prophylaxis study for chemotherapy-induced neutropenia in hematologic malignancies
ChiCTR2500098745Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in hematopoietic malignancies, acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL) and 1 more, sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of grade 3-4 chemotherapy-induced neutropenia in cycle 1. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
hematopoietic malignanciesacute lymphoblastic leukemia (ALL)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR2500098745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098745.